LBT Innovations Limited ( (AU:CC5) ) has shared an announcement.
Clever Culture Systems Ltd has reported its second consecutive quarter of positive cashflow operations, driven by strong sales momentum for its APAS® Independence system in the pharmaceutical manufacturing sector. The company has seen significant progress with major clients like AstraZeneca and Bristol Myers Squibb, and is expanding its sales pipeline with over 40 active customer opportunities. The upcoming launch of the APAS® contact plate application is expected to further enhance sales prospects, positioning the company for continued growth and strengthening its market presence.
More about LBT Innovations Limited
Clever Culture Systems Ltd is an Australian medical technology company specializing in microbiology automation using artificial intelligence. The company focuses on developing and commercializing the APAS® Independence system, which is designed for use in the pharmaceutical manufacturing sector to automate culture plate reading processes.
YTD Price Performance: -20.0%
Average Trading Volume: 689,874
Technical Sentiment Signal: Sell
Current Market Cap: A$28.25M
Find detailed analytics on CC5 stock on TipRanks’ Stock Analysis page.